In another study, Shubhmita et al. employed a multi-adjuvant strategy combining ovalbumin with DMXAA and compound 522, which significantly enhanced CD8+ T cell and NK cell responses, leading to tumor suppression and improved survival compared to controls [75]. This evidence concerns the gene CD8A and neoplasm.